Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
talquetamab + pomalidomide
- Development stage
- Phase 1
- Lead developer
- Janssen Research & Development
- Modality
- T-cell Engagers → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Small Molecules
- Administration
- Subcutaneous (talquetamab), Oral (pomalidomide)
01
Overview
Talquetamab + pomalidomide is an experimental combination regimen under evaluation for the treatment of relapsed/refractory multiple myeloma. **Talquetamab** is a bispecific monoclonal antibody targeting CD3 (on T-cells) and GPRC5D (on myeloma plasma cells), redirecting T-cell cytotoxicity toward myeloma cells by facilitating the formation of an immune synapse and activation of T-cell-mediated killing. **Pomalidomide** is an immunomodulatory small molecule (IMiD) that inhibits myeloma cell growth and augments T-cell and NK-cell activity. The combination enhances T-cell activation, the release of cytotoxic granules (granzyme B, perforin), and decreases regulatory T-cell frequency, resulting in improved anti-myeloma activity[1][2][4][5]. Clinical trials (MonumenTAL-2, MonumenTAL-3) have shown high overall response rates and manageable toxicity profiles for this combination in patients with heavily pretreated and high-risk myeloma.
- Other names
- talquetamab plus pomalidomideTal-P
02
Targets
CRBN (Cereblon)GPRC5DIKZF1 (Ikaros family zinc finger protein 1)IKZF3 (Zinc finger protein Aiolos)CD3 (T-cell surface glycoprotein CD3)
Beyond the preview
Go deeper on talquetamab + pomalidomide.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on talquetamab + pomalidomide.